Monitoring opioids in Europe: The need for shared definitions and measuring drivers of opioid use and related harms

G. A. KALKMAN ; W. VAN DEN BRINK ; M. PIERCE ; F. ATSMA ; K. C. P. VISSERS ; H. J. SCHERS ; R. T. M. VAN DONGEN ; C. KRAMERS ; A. F. A. SCHELLEKENS | 2022
Dans European Addiction Research (Vol.28, n°3, May 2022) Article : Périodique

The past 20 years, the USA is facing a serious opioid crisis initiated by an increase in prescription opioid use. Europe has also seen an increase in prescription opioid use, but the extent of related harm is still largely unknown. Given the imp[...]

Plus d'info

Ajouter à la sélection

Lien externe

Often overlooked and ignored, but do not underestimate its relevance: ADHD in addiction - Addiction in ADHD [Editorial]

A. F. A. SCHELLEKENS ; W. VAN DEN BRINK ; F. KIEFER ; A. E. GOUDRIAAN | 2020
Dans European Addiction Research (Vol.26, n°4-5, August 2020) Article : Périodique

This special issue of European Addiction Research (EAR) ratifies that there is an urgent need to foreground the initially ignored and then underestimated topic of an addiction-ADHD comorbidity, and to acknowledge the 10th anniversary of the Inte[...]

Plus d'info

Ajouter à la sélection

Lien externe

Unity in diversity: A systematic review on the GHB using population

B. A. G. DIJKSTRA ; H. BEURMANJER ; A. E. GOUDRIAAN ; A. F. A. SCHELLEKENS ; E. A. G. JOOSTEN | 2021
Dans International Journal of Drug Policy (Vol.94, August 2021) Article : Périodique

Background: Over the past decades gamma-hydroxybutyrate (GHB) has emerged as a popular drug with high potential of (ab)use due to its euphoric and relaxing effects. An overview of different populations using GHB is urgently needed, since this wo[...]

Plus d'info

Ajouter à la sélection